Summary
Cepheid is a molecular diagnostic company which develops, manufactures, and markets accurate and easy-to-use molecular systems and tests for clinical and non-clinical markets. The company offers invitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; systems that integrate sample preparation, DNA amplification and detection and analyze complex biological samples in our proprietary test cartridges; industrial reagents and parts and accessories for its systems. The company operates through its subsidiaries in France, Sweden, the US, Japan, Germany, South Africa, the UK, Belgium, Australia, the UAE, China, Italy, Singapore, Brazil, India, and Hong Kong. Cepheid is headquartered in Sunnyvale, California, the US.
Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cepheid, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cepheid, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cepheid, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cepheid, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Cepheid, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cepheid, Medical Equipment, Deal Details 11
Partnerships 11
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 11
Novacyt Enters into Partnership with Cepheid 12
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 12
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 13
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 14
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 15
InGen BioSciences Enters Into Distribution Agreement With Quidel 16
InGen BioSciences Enters Into Distribution Agreement With Diagnostic Hybrids 17
Life Technologies Enters Into Co-Marketing Agreement With Quidel 17
Cepheid Enters Into Co-Development Agreement With FIND 18
Equity Offering 19
Quidel Completes Underwritten Public Offering Of US$60 Million 19
Debt Offering 21
Quidel Prices Public Offering of 3.25% Senior Notes Due 2020 21
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 22
Acquisition 23
Danaher Acquires Cepheid 23
Quidel Acquires AnDiaTec, Molecular Diagnostics Company 25
Quidel Acquires BioHelix, Molecular Diagnostic Company, For US$10 Million 26
Cepheid - Key Competitors 27
Key Employees 28
Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results 31
Apr 28, 2016: Cepheid Reports First Quarter 2016 Results 32
Feb 02, 2016: Cepheid Reports Fourth Quarter And Full Year 2015 Results 33
Corporate Communications 34
Feb 10, 2016: Cepheid Announces Appointment of President and Chief Operating Officer and Welcomes Executive Vice President of Engineering and Operations 34
Legal and Regulatory 35
Jan 07, 2016: USAID And Cepheid Plan Collaboration To Accelerate Global Diagnosis Of Multidrug-Resistant Tuberculosis 35
Product News 36
03/09/2016: Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant 'Superbugs' 36
Product Approvals 37
Mar 09, 2016: Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant 'Superbugs' 37
Other Significant Developments 38
Apr 21, 2016: Cepheid Announces Partner Distribution Agreement With Medline 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
Cepheid, Medical Equipment, Key Facts, 2015 1
Cepheid, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Cepheid, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cepheid, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Cepheid, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cepheid, Deals By Market, 2011 to YTD 2017 9
Cepheid, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 11
Novacyt Enters into Partnership with Cepheid 12
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 12
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 13
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 14
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 15
InGen BioSciences Enters Into Distribution Agreement With Quidel 16
InGen BioSciences Enters Into Distribution Agreement With Diagnostic Hybrids 17
Life Technologies Enters Into Co-Marketing Agreement With Quidel 17
Cepheid Enters Into Co-Development Agreement With FIND 18
Quidel Completes Underwritten Public Offering Of US$60 Million 19
Quidel Prices Public Offering of 3.25% Senior Notes Due 2020 21
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 22
Danaher Acquires Cepheid 23
Quidel Acquires AnDiaTec, Molecular Diagnostics Company 25
Quidel Acquires BioHelix, Molecular Diagnostic Company, For US$10 Million 26
Cepheid, Key Competitors 27
Cepheid, Key Employees 28
Cepheid, Subsidiaries 29
List of Figures
Cepheid, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Cepheid, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Cepheid, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Cepheid, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Cepheid, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Cepheid, Medical Equipment, Deals by Type, 2011 to YTD 2017 7
Cepheid, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Cepheid, Medical Equipment, Deals by Market, 2011 to YTD 2017 9
